2 Mid-Cap Stocks to Research Further and 1 We Question
By:
StockStory
September 11, 2025 at 00:36 AM EDT
Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. However, they face intense competition from scaled industry giants and can be disrupted by new innovative players vying for a slice of the pie. These dynamics can rattle even the most seasoned professionals, which is why we started StockStory - to help you separate the good companies from the bad. That said, here are two mid-cap stocks with massive growth potential and one that may have trouble. One Mid-Cap Stock to Sell:Annaly Capital Management (NLY)Market Cap: $14.19 billion Operating as a real estate investment trust since 1996 with a focus on generating income from interest rate spreads, Annaly Capital Management (NYSE: NLY) is a diversified capital manager that invests in agency mortgage-backed securities, residential mortgage loans, and mortgage servicing rights. Why Do We Pass on NLY?
At $22.20 per share, Annaly Capital Management trades at 1.2x forward P/B. Read our free research report to see why you should think twice about including NLY in your portfolio. Two Mid-Cap Stocks to Watch:Dynatrace (DT)Market Cap: $14.37 billion With its platform processing over 30 trillion pieces of IT performance data daily, Dynatrace (NYSE: DT) provides an AI-powered platform that helps organizations monitor, secure, and optimize their applications and IT infrastructure across cloud environments. Why Do We Like DT?
Dynatrace is trading at $47.66 per share, or 7.1x forward price-to-sales. Is now a good time to buy? Find out in our full research report, it’s free. Medpace (MEDP)Market Cap: $13.39 billion Founded in 1992 as a scientifically-driven alternative to traditional contract research organizations, Medpace (NASDAQ: MEDP) provides outsourced clinical trial management and research services to help pharmaceutical, biotechnology, and medical device companies develop new treatments. Why Is MEDP on Our Radar?
Medpace’s stock price of $476.69 implies a valuation ratio of 38.8x forward P/E. Is now the right time to buy? See for yourself in our in-depth research report, it’s free. High-Quality Stocks for All Market ConditionsWhen Trump unveiled his aggressive tariff plan in April 2025, markets tanked as investors feared a full-blown trade war. But those who panicked and sold missed the subsequent rebound that’s already erased most losses. Don’t let fear keep you from great opportunities and take a look at Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today for free. Find your next big winner with StockStory today. Find your next big winner with StockStory today StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. More NewsView More
3 Stocks Poised to Benefit From Google’s AI Breakthough ↗
December 03, 2025
Beyond NVIDIA: 5 Semiconductor Stocks Set to Dominate 2026 ↗
December 03, 2025
3 Stocks You’ll Wish You Bought Before 2026 ↗
December 03, 2025
Via MarketBeat
Wall Street Punished CrowdStrike for Beating Earnings? Seriously? ↗
December 03, 2025
Via MarketBeat
Tickers
CRWD
Okta: Excuses to Sell Vs. Reasons to Buy ↗
December 03, 2025
Via MarketBeat
Recent QuotesView More
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes. By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
|
